• Home
  • Assessment paper
  • Veracyte (VCYT) Announces New Data Published in JNCI Demonstrates Its Decipher Prostate Genomic Classifier Can Improve Identification of Aggressive Prostate Cancer in African American Men

Veracyte (VCYT) Announces New Data Published in JNCI Demonstrates Its Decipher Prostate Genomic Classifier Can Improve Identification of Aggressive Prostate Cancer in African American Men

By on September 22, 2022 0

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.


Veracyte, Inc.. (Nasdaq: VCYT) announced that data released today in the Journal of the National Cancer Institute demonstrate that the Company’s Decipher Prostate Genomic Classifier can help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease. Data from the prospective, multi-site VANDAAM Phase 2 clinical study suggest that genomic testing may offer robust improvement over clinical factors alone in risk-stratifying prostate cancer in African American men, which may help reduce disparities in prostate cancer outcomes. .

“While African-American men have both a higher incidence and mortality associated with prostate cancer, few prospective studies maximize the recruitment of these men to provide an unbiased assessment of the genomic processes underlying these disparities,” said Kosj Yamoah, MD, Ph.D., chair, Department of Radiation Oncology, Moffitt Cancer Center, and senior author of the published paper. “We very intentionally recruited a balanced sample of men in this study, but we first prioritized recruiting African American men to ensure that we had a representative sample of this population, which has historically been underserved in clinical trials for prostate cancer. Integration of the Decipher classifier with traditional clinical risk factors has been shown to improve identification of the subset of African American men with more aggressive disease. This information could help guide targeted interventions and treatment strategies to improve outcomes in this population.

The Decipher Prostate Genomic Classifier is a 22-gene prognostic biomarker that provides a low, intermediate, or high score indicating an individual patient’s cancer aggressiveness, to help healthcare professionals more accurately categorize risk and select the appropriate treatment.

The VANDAAM trial recruited men with low- or intermediate-risk prostate cancer as classified by the National Comprehensive Cancer Network (NCCN)® guidelines for prostate cancer. For the current analysis, the researchers identified a clinically balanced cohort of 226 men (113 African American men and 113 non-African American men) from the study and performed genomic analysis using the Decipher classifier Prostate to generate Decipher risk scores.

The results show that a higher proportion of African-American men with low- and intermediate-risk prostate cancer favorable to NCCN (18% and 37.8%, respectively) had higher Decipher scores than non-African American men. Men who identified as African American were more than twice as likely as non-African American men to have their cancer reclassified from NCCN low or intermediate risk based on a high Decipher score (known as genomic risk name for reclassification or GrR; risk = 2.23; 95% CI). Additionally, the data shows that younger African American men had higher Decipher scores, whereas in non-African American men, a higher risk of metastasis scores was seen in older men.

“This study demonstrates that classification of prostate cancer risk using clinical factors alone may be suboptimal and may underestimate African American men’s risk of harboring aggressive disease,” Elai said. Davicioni, Ph.D., Veracyte Medical Director, Urology. “We commend the study team for undertaking the first prospective trial to use genomic classifiers as part of the trial design, and for their efforts to help close the clinical disparity gap in improving risk stratification in African American men with prostate cancer.”